Enfortumab vedotin monotherapy or its combination with pembrolizumab could significantly evolve the treatment landscape for urothelial cancer. Arlene Siefker-Radtke, MD: Looking at the data presented, ...
The current research frontier in blastic plasmacytoid dendritic cell neoplasm (BPDCN) is moving toward combination triplet ...
Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates. In this episode, experts examine combination ...
Please provide your email address to receive an email when new articles are posted on . Among adults with atherosclerotic CVD at very high risk, moderate-intensity statin plus ezetimibe combination ...
New research led by scientists at VCU Massey Comprehensive Cancer Center suggests that a class of drugs known as MCL-1 (myeloid leukemia cell-1) inhibitors interact with a type of kinase inhibitor ...
Development of bifunctional CRBN-SOS1 degraders for treatment of mutant KRAS cancers. TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results